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Published in this edition of the BJC are the results of a randomized
phase II vaccine trial for patients with colorectal cancer. The trial,
one of the largest to date, investigated the use of an anti-idiotypic
antibody mimicking a tumour-associated antigen, in patients with
advanced colorectal cancer. No survival advantage was demon-
strated with the use of the vaccine. In an age where there is
increased interest in the use of cancer vaccines it is important
to assess the justification for their continued development. 
Vaccine immunology 
Central to the renewed interest in cancer vaccine therapy is the
increased understanding of mechanisms involved in an antigen-
specific T-cell response, with animal studies demonstrating that
although the humoral immune system may be relevant, it is cell-
mediated immunity that is of critical importance in tumour protec-
tion (Golumbek et al, 1991; Dranoff et al, 1993). T cells recognize
antigen only when displayed on the surface of the target cell or
antigen-presenting cell as peptide fragments bound to the class I
and II molecules of the major histocompatibility complex (MHC).
MHC antigens are highly polymorphic, with different alleles
binding different peptide epitopes derived from the tumour
antigen. Class I MHC molecules, recognized by cytotoxic CD8+ T
cells, are present on the surface of virtually all nucleated cells.
Class II molecules, recognized by helper CD4+ T cells, are present
on the surface of professional antigen-presenting cells such as
dendritic cells. These highly specialized cells, which capture and
process antigens released by tumour cell breakdown, are therefore
able to present antigen to both cytotoxic and T-helper cells. 
An effective T-cell response is now known to also be dependent
on co-stimulatory molecules present at the time of antigen presen-
tation. T-cell receptor engagement in the absence of co-stimulation
results in T-cell tolerance. 
Limitations to the use of anti-idiotype vaccines 
Anti-idiotypic antibodies raised against the unique antigen-
binding site of an antibody may functionally mimic the antigen on
the tumour-cell surface. Anti-idiotypic antibodies can therefore 
be used as surrogate tumour antigens for vaccine therapy. Where
the anti-idiotypic antibody bears structural similarity to the
tumour antigen anti-idiotypic antibodies should induce an anti-
body response to the idiotype and therefore to the tumour antigen
itself. However, most B-cell epitopes will be to components of the
anti-idiotype that do not mimic the tumour antigen. 
Vaccine-based immunity is largely reliant upon the efficiency of
the antigen-presenting cell that initially presents the antigen.
Dendritic cells are the most effective antigen-presenting cells; one
of the primary goals of vaccine therapy is to target these cells.
Dendritic cells express Fc receptors that will bind anti-idiotypic
antibodies, allowing the antigen to be presented in the context of
class I and II MHC molecules, eliciting both cytotoxic and helper
T-cell responses. Anti-idiotypic antibody treatment can, therefore,
activate both arms of the immune system, in theory making them
attractive candidates for cancer vaccines. It has been argued that
the changed context of the epitope may facilitate the generation of
an immune response, however, unlike native antigens, which
contain several peptide epitopes capable of binding most MHC
molecules, anti-idiotypic antibodies contain a limited subset of all
potential peptide epitopes. They are therefore only likely to be
effective in patients with a permissive MHC haplotype. When the
tumour antigen that the idiotype mimics is known, computer-
predicted binding motifs can be identified from the homologous
regions, allowing clinicians to anticipate which patients may
benefit from the vaccine. If this is not possible because the tumour
antigen that the idiotype mimics has not yet been identified the
idiotype may contains epitopes that bind only to rare MHC haplo-
types and the vaccine will be ineffective for the majority of
patients. Furthermore vaccines that contain only a limited number
of T-cell epitopes may lack class I or class II motifs, potentially
leading to a sub-optimal immune response. An additional concern
with the use of minimal epitope vaccines is the increased potential
for immune selection of tumours with subtle genetic variations 
that no longer express the peptide epitope(s). Immunohistochemical
analysis of repeat biopsies from patients with metastatic melanoma
who had initially responded to a peptide vaccine, but who relapsed
despite the presence of peptide-specific cytotoxic T cells, revealed
gradual loss of antigen expression in association with disease
progression (Jager et al, 1997). Use of vaccines containing one or
more whole antigens should induce a polyclonal immune response
capable of recognizing multiple antigenic determinants and may
prevent tumour escape. 
Genetically modified cancer vaccines: a superior
approach? 
The majority of tumour antigens are self antigens, to which there
will be varying degrees of tolerance. Cancer vaccines must over-
come this tolerance and encourage the immune system to see the
antigen as foreign. It has been hypothesized in what is determined
the danger model (Matzinger, 1994) that it is the context in which
antigens are presented to the immune system that determines 
the outcome of antigen encounter. When an antigen is seen 
in the midst of inflammation and cellular damage that accom-
panies infection the outcome is typically activation. When an 
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these ‘danger’ signals, the outcome may be tolerance. Tumour
cells that develop with little inflammation, at least in the early
stages, result in tolerance. Cancer vaccines, unlike prophylactic
vaccines against infectious diseases, must activate an immune
response to an antigen to which it has already been exposed,
and therefore need to be more immunogenic than traditional
immunizations. 
Advances in molecular biological techniques have allowed the
development of vaccines that preclinical studies have demon-
strated to be much more immunogenic than the early generation
cancer vaccines. Molecular characterization of a variety of tumour
antigens have provided the means for genes encoding these anti-
gens to be configured as DNA, viral, or as genetically modified
dendritic cell or tumour cell vaccines. Genetic vaccines, particu-
larly viral-based systems, should allow more sustained antigen
expression than protein or peptide vaccines. 
One further advantage of molecular vaccines is the ability to
incorporate genes encoding key elements of the immune response
such as cytokines. The cytokine is produced in high concentrations
at the site of the vaccine, altering the immunological environment
and enhancing the activity of antigen-presenting cells and the acti-
vation of tumour-specific T cells. This is achieved without the side
effects of systemic cytokine treatment. A phase I trial comparing
GM-CSF gene transduced and non-transduced autologous renal
cell vaccines provided preliminary evidence of the enhanced
immunogenicity of the former by the induction of delayed type
hypersensitivity responses against autologous tumour (Simons et
al, 1997). Genes providing foreign helper T-cell epitopes such as
tetanus toxoid can also be included, allowing more efficient
priming of the immune response (King et al, 1998) and also
providing an easy immunological readout for the success or other-
wise of the clinical trial. 
DNA vaccines are probably the simplest and most inexpensive
genetic vaccine to generate. Having been shown to be effective 
in inducing anti-tumour immunity in several murine lymphoma
(Hawkins et al, 1993; Stevenson et al, 1995; Syrengelas et al,
1996; King et al, 1998) and myeloma models (King et al, 1998),
DNA vaccines are now entering clinical trials (Hawkins et al,
1997). Alternatives include recombinant viral vaccines that
provide more efficient and reliable gene transfer and thus may be
more potent vaccines than protein (Timmerman et al, 2001) or
plasmid vaccines (own observations). One further advantage of
the use of viral vectors is their intrinsic ability to initiate immune
responses, with inflammatory responses occurring as a result of
the viral infection creating the ‘danger’ signals necessary for
immune activation. Expression of viral (and therefore foreign
genes) should also act as an immunological adjuvant, further
enhancing the immune response. Some viruses, including vaccinia
viruses, are able to directly target antigen-presenting cells in vivo
allowing for efficient presentation of incorporated antigens.
Clinical trials of recombinant viral vectors are underway. A
vaccinia viral vector encoding the E6 and E7 oncogenic proteins
from HPV 16 and 17 was used to vaccinate patients with late-stage
cervical cancer (Borysiewicz et al, 1996). The one patient that had
a sustained clinical response to the vaccine also developed HPV-
specific cytotoxic T cells. 
Dendritic cells are key orchestrators of the immune response.
Encouraging results with clinical trials involving dendritic cells,
generated ex vivo, and loaded with tumour antigen prior to 
re-infusion (Hsu et al, 1996; Nestle et al, 1998; Kugler et al, 2000)
have led to an interest in the use of genetically modified dendritic
cells vaccines, with viral vectors currently the most efficient way
to transduce dendritic cells (Arthur et al, 1997). One limitation to
the use of viral vectors may be the level of pre-existing immunity
to the vector. In murine models virally infected dendritic cell
vaccines are more effective at inducing anti-tumour immunity in
the presence of pre-existing anti-viral immunity than the recombi-
nant viral vector alone (Brossart et al, 1997; Kaplan et al, 1999). 
Tumour burden and the success of vaccine therapy 
The authors cite large tumour burden and advanced disease as one
of the reasons for failure of the anti-idiotypic antibody trial.
Certainly, it is becoming increasingly clear that as well as 
developing passive mechanisms for evading the immune response
– such as antigen loss or MHC down-regulation – tumours them-
selves can actively inhibit the immune response. In a recent model
mice vaccinated with irradiated tumour cells, genetically engi-
neered to secrete GM-CSF and given simultaneously with a
tumour challenge, were protected from that tumour challenge,
with the protection mediated by T cells (Hsieh et al, 2000). Mice
given the vaccine a week after tumour challenge were no longer
protected, although the anti-tumor activity of the T cells could be
restored following re-stimulation in vitro. It was demonstrated that
the immunosuppressive factors IL-10 and TGF-beta, secreted by
the tumour cells, inhibited T-cell function. It is likely that similar
mechanisms exist in man, with one study finding raised IL-10
levels on 40 out of 99 patients with a range of solid tumours (Fortis
et al, 1996). 
Evaluation of vaccine therapy: the importance of
immunological endpoints 
It is anticipated, then, that cancer vaccines will be more effective
when given to patients with minimal levels of disease and may
show no clinical effect in advanced disease. To justify the progres-
sion of a cancer vaccine through clinical trials (once initial studies
have confirmed the safety of the approach), immunological
endpoints are needed in order to improve the vaccine as necessary,
and to optimize the vaccination schedule. It is possible that further
optimization of the 105AD7 vaccine method could enhance the
immune response and produce clear humoral or cytotoxic T-cell
responses. 
Difficulties in assessing the immune response to a vaccine
hamper all vaccine trials. It is still not yet established which
immune effectors are needed for the optimal anti-tumour immune
response and therefore trials should examine different parameters,
including both arms of the immune response. Enzyme-linked
immunosorbent assays (ELISAs) reliably assess the humoral
immune response induced by vaccination. Assessment of the
cellular immune response is more difficult. Many assays require
one or more rounds of in vitro stimulation of post-vaccination T
cells, which potentially reduces the relevance of any result to what
is actually happening in vivo. Assays such as the enzyme-linked
immunospot (ELISpot), an interferon-g-release assay which can
detect the frequency of specific cytotoxic lymphocytes, are
gaining popularity, but the relative importance of any positive
result to clinical outcome remains unclear. The assay which
currently appears in a number of trials to correlate most strongly
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testing (Berd et al, 1990; Simons et al, 1997; Harris et al, 2000). 
Induction of autoimmune disease? 
Clinical trials to date have demonstrated the safety of vaccine
therapy for cancer. One consideration for vaccine trials is the
choice of tumour antigen(s) incorporated in the vaccine with
potentially the worst outcome of vaccinating against self-antigens
being the induction of autoimmunity – it is well recognized that
20% of patients with melanoma that respond to IL-2 develop
vitiligo. 105AD7 mimics CD55, a widely distributed complement
regulatory protein that is over-expressed by a number of tumours.
The therapeutic rationale thus depends on the ability of the
immune response to distinguish the level of antigen expression.
Indeed, cytotoxic T cells are able to identify tumour antigens that
are over-expressed by tumour cells but are unable to recognize the
same antigen on cells that express normal levels of the antigen. As
an example of such a selective effect, vaccination of mice with
murine p53 epitopes prevents the growth of tumours that contain
high levels of the protein, without any damage to normal tissues
(Mayordomo et al, 1996; Vierboom et al, 1997). There are, how-
ever, other mouse experiments where powerful vaccines induce
strong and effective anti-tumor immune responses but at the
expense of major autoimmune toxicity (Ludewig et al, 2000). 
Thus if one proposed to use more powerful methods of vaccina-
tion to an antigen such as CD55 (which is expressed by many cells
of the immune system), a degree of caution would be warranted
because of the potentially disastrous consequences. Examples of
other potential targets that are widely distributed include the Her2
growth factor receptor, which is over-expressed in many common
tumours but also found in many normal tissues. Until the actual
risk of autoimmunity is more quantifiable it may be prudent to
initially vaccinate against tumour antigens whose expression is
limited to less crucial cells. 
CONCLUSIONS 
Currently there are no proven tumour vaccines and this is a fur-
ther negative study. The trial is large, well conducted and there 
is no reason to doubt the result. Where do we go from here?
Undoubtedly, vaccine design and antigen choice need careful
consideration. Reliable and relevant immunological assays are
needed as surrogate markers for the potential clinical benefit of
any cancer vaccine, particularly as patients vaccinated in phase I/II
trials are likely to have advanced disease. As more effective
vaccines are developed the risk of autoimmunity will increase and
must be carefully monitored and (where necessary) treated. 
Nevertheless, there is great hope that cancer vaccines will offer
a useful addition to more conventional oncological therapies. Pre-
clinical studies are demonstrating the superiority of vaccines that
take full advantage of recent advances in immunological under-
standing and molecular techniques over older vaccine formula-
tions. It is anticipated that some of these advances will translate
into successful clinical trials. 
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